Catalyst Pharmaceuticals
Update in progressCPRX (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare diseases in the United States. Its offerings include Firdapse for Lambert-Eaton myasthenic syndrome, Fycompa for focal onset and tonic-clonic seizures, and AGAMREE for Duchenne muscular dystrophy. It has licensing deals with BioMarin and a collaboration with Endo Ventures for generic Sabril. Founded in 2002, based in Coral Gables, Florida.
Company score
- Sentiment
- 0.17
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.18
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.06
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNGM
- LocationUnited States
- CEOMr. Richard John Daly M.B.A.
- Founded2002
- Employees182
- Websitecatalystpharma.com
Identifiers
- ISINUS14888U1016
- FIGIBBG000GZDC67
- LEI5299004O0R5XXLA5H544
- CUSIP14888U101
- CIK0001369568